Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|June 28, 2006

Schering-Plough Establishes Brazilian Subsidiary

Schering-Plough (Kenilworth, NJ, www.sch-plough.com) will establish Schering-Plough Produtos Farmaceuticos Limitada in Sao Paulo, Brazil, to market its core products.

Schering-Plough (Kenilworth, NJ, www.sch-plough.com) will establish Schering-Plough Produtos Farmaceuticos Limitada in Sao Paulo, Brazil, to market its core products. The company will also restructure its agreement (originally formed in 1991) with Brazil-based drug manufacturer Mantefarma, now to be known as Mantecorp, in an effort to increase Schering’s presence in Latin America. Schering-Plough Produtos Farmaceuticos Limitada will commercialize specialty care products, including hepatitis C treatment PegIntron (peginterferon alfa-2b) and cancer-fighting drugs Temodal (temozolomide) and Caelyx (pegylated liposomal doxorubicin HCI).


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.